Podcast explores how intratumoral injections may spark systemic cancer immunity

In a recent episode of BioSpace's Denatured podcast, host Jennifer C. Smith-Parker spoke with Lewis Bender, CEO of Intensity Therapeutics, and Paul-Peter Tak, president and CEO of Candel Therapeutics.

The guests explained that delivering therapy directly into a tumor can provoke a broader immune response throughout the body, potentially turning a local injection into a systemic anticancer strategy. They described how this approach could reshape the foundational platform of immuno‑oncology.

Both executives emphasized the promise of intratumoral therapy to complement existing treatments and to expand the toolbox for fighting cancer, while noting that further clinical validation will be needed.